Skip to content
Home/Companies/Biotech/Olink Proteomics

Olink Proteomics

Biotech·Sweden·Exited 2021·Held 2yr
Entry
2019
Hold
2yr
Exit
2021

Who owns Olink Proteomics?

Olink Proteomics was owned by Summa Equity through Summa Equity Fund II (2019 vintage) from 2019 to 2021, exited via IPO.

Hand-verified · updated 2026-08-18

Summa Equity
Investor
Summa Equity
Summa Equity Fund II · 2019 · Buyout

Key facts

HQSweden
SectorBiotech
StatusAcquired
Exit Type
IPO
Buyer
–
MOIC
–
Exit Year
2021

More from Summa Equity Fund II

Other portfolio companies in the same fund.

Axion Biosystems
Active
MedTechUS· 2021
G-CON Manufacturing
Exited 2025
HealthcareUS· 2021
to
Holdbart
Active
ConsumerNorway· 2021
myneva
myneva
Active
SoftwareGermany· 2021
Nofitech
Active
IndustrialsNorway· 2021
Sengenics
Active
BiotechSingapore· 2020

More PE-backed in Biotech

Comparable biotech deals from other GPs.

Abbisko Healthcare
Active
The Carlyle GroupChina
Adagene
Active
General AtlanticChina
Advanced Cell Diagnostics
Active
Summit PartnersUS
Akero Therapeutics
Akero Therapeutics
Active
General AtlanticUS
Aldevron
Aldevron
Active
TA AssociatesUS
Alloy Therapeutics
Alloy Therapeutics
Active
Mubadala CapitalUS
Track Olink Proteomics

Save this record to your watchlist and pick up your research where you left off. No spam.

Create free account

Who could buy Olink Proteomics?

7 strategic and 113financial buyers match this company's sector and geography profile, ranked from verified European deal history.

Find likely buyers

Get the full record on Olink Proteomics.

Free. No credit card. 30 seconds. Exit buyers and MOIC on Pro.

Hand-checked deal notes on this investment
Save this company to your watchlist
Exit buyer and MOIC on this deal (Pro)
or
Continue with email

Already a member? Sign in

Look up another firm or company
Data refreshed weekly · Sourced from public filings · Report an issue